SCIENTIFIC PROGRAMME
SESSION I
THE GENOMIC AND
EPIGENOMIC LANDSCAPE
OF CLL AND CLINICAL
CONSEQUENCES
SESSION II
THE ROLE OF BCR
ACTIVATION AND
SIGNALLING FOR CLL
SESSION III
THERAPEUTIC OPTIONS
FOR CLL
SESSION IV
LONG TERM FOLLOW
UP OF CLINICAL TRIALS
VERSUS REAL WORLD
DATA (OUTSIDE CLINICAL
TRIALS DATA-OCT)
SESSION V
THE INCREASING ROLE
OF THE LEUKAEMIC
MICROENVIRONMENT
SESSION VI
THERAPEUTIC OPTIONS 2 :
THE USE OF CELLULAR
AND NON-CELLULAR
IMMUNOTHERAPIES IN
CLL
SESSION VII
EFFICACY THROUGH
SAFETY
SESSION VIII
CLONAL HETEROGENEITY,
CLONAL EVOLUTION AND
MECHANISMS OF DRUG
RESISTANCE
SESSION IX
CONTRASTING
THERAPEUTIC CONCEPTS
SELECTED ABSTRACTS
FOR AN ORAL
PRESENTATION
SELECTED ABSTRACTS
FOR A POSTER
PRESENTATION
FACULTY DISCLOSURES
95% CI 0.185-0.665; p=0.001). 20 patients of the len and 19 of the placebo group received
subsequent treatment. The most frequent therapy was Ibrutinib in 66% of the cases. The 5-
year overall survival rate was 79% in the len group and 87% in the placebo group (hazard ratio
1.534, 95% CI 0.415-5.669; p=0.521). 9 patients in the len and 3 in the placebo group died.
Haematological (ALL) and solid tumour second primary malignancies were reported in 3 (5%)
and 4 (7%) patients of the len group, compared with 0 and 2 (7%) in the placebo group.
Conclusion: Lenalidomide was an efficacious maintenance treatment in high risk CLL and
improved progression-free as compared to placebo without an overall survival benefit. In view
of three unexpected ALL cases observed in the len Group, maintenance with len cannot be
generally recommended in CLL. Further investigations are warranted to analyse the
unexpectedly high incidence of ALL.
POSTER 31